QIAGEN reaffirms FY12 EPS view $1.04-1.06, consensus $1.00 Sees revenue up approximately 8-9% CER on a mix of contributions from the acquisitions of Cellestis and Ipsogen in 2011 and AmniSure in May 2012, as well as growth in the rest of the business. Full-year reported sales are expected to be adversely affected by currency movements against the U.S. dollar, QIAGEN's reporting currency.This guidance takes into account approximately half a cent of dilution expected on adjusted EPS results in the fourth quarter of 2012 from the combined effect of the share repurchase program as well as higher interest expenses incurred through the U.S. private placement. These expectations do not take into account any further acquisitions that could be completed in 2012.
QIAGEN sees FY15 adjusted EPS $1.16-1.18, consensus $1.10 Sees FY15 adjusted net sales to rise approximately 4% CER in 2015, as growth of about 7-8% CER in the core portfolio exceeds the adverse impact of approximately 3-4 percentage points from lower U.S. HPV sales. FY15 revenue consensus $1.32B.